Imuran, Methotrexate, 6-MP

Withdrawal of thiopurines in Crohn’s disease treated with scheduled adalimumab maintenance: a prospective randomised clinical trial (DIAMOND2).

May 2, 2019May 2, 2019 ibdwatch

Related Articles Withdrawal of thiopurines in Crohn’s disease treated with scheduled adalimumab maintenance: a prospective randomised clinical trial (DIAMOND2). J Gastroenterol. 2019 Apr 30;: Authors: Hisamatsu T, Kato S, Kunisaki R, Matsuura M, Nagahori M, Motoya S, Esaki M, Fukata N, Inoue S, Sugaya T, Sakuraba H, Hirai F, Watanabe K, Kanai T, Naganuma M, Nakase H, Suzuki Y, Watanabe M, Hibi T, Nojima M, Matsumoto T, DIAMOND2 Study Group Abstract BACKGROUND: The risk:benefit ratio of concomitant use of thiopurines with scheduled adalimumab (ADA) maintenance therapy for Crohn’s disease is…

Low-dose Methotrexate has Similar Outcomes to High-dose Methotrexate in Combination with Anti-TNF Therapy in Inflammatory Bowel Diseases.

March 20, 2019 ibdwatch

Low-dose Methotrexate has Similar Outcomes to High-dose Methotrexate in Combination with Anti-TNF Therapy in Inflammatory Bowel Diseases. J Crohns Colitis. 2019 Mar 19;: Authors: Borren NZ, Luther J, Colizzo FP, Garber JG, Khalili H, Ananthakrishnan AN Abstract BACKGROUND AND AIMS: Methotrexate [MTX] is a well-known immunomodulator in the treatment of inflammatory bowel disease [IBD] and is often combined with biologic agents. The ideal MTX dose for combination therapy has not been determined. This study aimed to investigate the effect of varying doses of MTX on efficacy and safety outcomes when…

The Inflammatory Bowel Disease Drug Azathioprine Induces Autophagy via mTORC1 and the Unfolded Protein Response Sensor PERK.

March 20, 2019March 20, 2019 ibdwatch

The Inflammatory Bowel Disease Drug Azathioprine Induces Autophagy via mTORC1 and the Unfolded Protein Response Sensor PERK. Inflamm Bowel Dis. 2019 Mar 19;: Authors: Hooper KM, Casanova V, Kemp S, Staines KA, Satsangi J, Barlow PG, Henderson P, Stevens C Abstract BACKGROUND: Genetic studies have strongly linked autophagy to Crohn’s disease (CD), and stimulating autophagy in CD patients may be therapeutically beneficial. The aim of this study was to evaluate the effect of current inflammatory bowel disease (IBD) drugs on autophagy and investigate molecular mechanisms of action and functional outcomes…

Mortality Associated With Development of Squamous Cell Cancer in Patients With Inflammatory Bowel Disease Receiving Treatment With Thiopurines.

March 12, 2019March 12, 2019 ibdwatch

Related Articles Mortality Associated With Development of Squamous Cell Cancer in Patients With Inflammatory Bowel Disease Receiving Treatment With Thiopurines. Clin Gastroenterol Hepatol. 2019 Mar 07;: Authors: Khan N, Lee H, Trivedi C, Kavani H, Medvedeva E, Xie D, Lewis JD, Yang YX Abstract BACKGROUND & AIMS: Treatment with thiopurines is associated with an increased risk of squamous cell carcinoma of the skin (SCC) in patients with inflammatory bowel diseases (IBD). We studied outcomes of patients with IBD who developed SCC while receiving thiopurine therapy. METHODS: We conducted a retrospective…

Thiopurine Therapy for Inflammatory Bowel Disease During Pregnancy Is Not Associated with Anemia in the Infant.

March 1, 2019March 1, 2019 ibdwatch

Related Articles Thiopurine Therapy for Inflammatory Bowel Disease During Pregnancy Is Not Associated with Anemia in the Infant. Dig Dis Sci. 2019 Feb 28;: Authors: Koslowsky B, Sadeh C, Grisaru-Granovsky S, Miskin H, Goldin E, Bar-Gil Shitrit A Abstract INTRODUCTION: Thiopurine exposure throughout pregnancy in patients with inflammatory bowel diseases (IBD) is common and teratogenically safe. Late consequences of in utero exposure to thiopurines and its metabolite, 6-thioguanine nucleotides (6-TGN), such as neonatal and infant anemia are still disputed. AIM: To evaluate whether 6-TGN exposure during pregnancy influences anemia in…

Association of Genetic Variants in NUDT15 With Thiopurine-Induced Myelosuppression in Patients With Inflammatory Bowel Disease.

February 27, 2019February 27, 2019 ibdwatch

Association of Genetic Variants in NUDT15 With Thiopurine-Induced Myelosuppression in Patients With Inflammatory Bowel Disease. JAMA. 2019 Feb 26;321(8):773-785 Authors: Walker GJ, Harrison JW, Heap GA, Voskuil MD, Andersen V, Anderson CA, Ananthakrishnan AN, Barrett JC, Beaugerie L, Bewshea CM, Cole AT, Cummings FR, Daly MJ, Ellul P, Fedorak RN, Festen EAM, Florin TH, Gaya DR, Halfvarson J, Hart AL, Heerasing NM, Hendy P, Irving PM, Jones SE, Koskela J, Lindsay JO, Mansfield JC, McGovern D, Parkes M, Pollok RCG, Ramakrishnan S, Rampton DS, Rivas MA, Russell RK, Schultz M,…

Concerns and side effects of azathioprine during adalimumab induction and maintenance therapy for Japanese patients with Crohn’s disease: a sub-analysis of a prospective randomized clinical trial (DIAMOND study).

February 13, 2019February 13, 2019 ibdwatch

Concerns and side effects of azathioprine during adalimumab induction and maintenance therapy for Japanese patients with Crohn’s disease: a sub-analysis of a prospective randomized clinical trial (DIAMOND study). J Crohns Colitis. 2019 Feb 08;: Authors: Hisamatsu T, Matsumoto T, Watanabe K, Nakase H, Motoya S, Yoshimura N, Ishida T, Kato S, Nakagawa T, Esaki M, Nagahori M, Matsui T, Naito Y, Kanai T, Suzuki Y, Nojima M, Watanabe M, Hibi T, DIAMOND study group Abstract Background: Combining a thiopurine with the human anti-tumor necrosis factor- monoclonal antibody adalimumab for Crohn’s…

Genotype-guided thiopurine dosing does not lead to additional costs in patients with inflammatory bowel disease.

January 31, 2019January 31, 2019 ibdwatch

Genotype-guided thiopurine dosing does not lead to additional costs in patients with inflammatory bowel disease. J Crohns Colitis. 2019 Jan 30;: Authors: Sluiter RL, van Marrewijk C, de Jong D, Scheffer H, Guchelaar HJ, Derijks L, Wong DR, Hooymans P, Vermeulen SH, Verbeek ALM, Franke B, van der Wilt GJ, Kievit W, Coenen MJH Abstract Background and aims: Decreased thiopurine S-methyltransferase (TPMT) enzyme activity increases the risk of hematologic adverse drug reactions (ADR) in patients treated with thiopurines. Clinical studies have shown that in patients with inflammatory bowel disease (IBD),…

Withdrawal of Azathioprine in Inflammatory Bowel Disease Patients Who Sustain Remission: New Risk Factors for Relapse.

January 4, 2019January 4, 2019 ibdwatch

Related Articles Withdrawal of Azathioprine in Inflammatory Bowel Disease Patients Who Sustain Remission: New Risk Factors for Relapse. Dig Dis Sci. 2019 Jan 02;: Authors: Iborra M, Herreras J, Boscá-Watts MM, Cortés X, Trejo G, Cerrillo E, Hervás D, Mínguez M, Beltrán B, Nos P Abstract BACKGROUND: The benefits of immunosuppressants for sustaining remission and preventing flares of IBD are well known. However, optimal timing for withdrawal has not been determined. AIMS: The objective of this study was to calculate the risk of relapse and predictors after withdrawal of azathioprine…

Usefulness of Thiopurine Monotherapy for Crohn’s Disease in the Era of Biologics: A Long-Term Single-Center Experience.

December 27, 2018December 27, 2018 ibdwatch

Related Articles Usefulness of Thiopurine Monotherapy for Crohn’s Disease in the Era of Biologics: A Long-Term Single-Center Experience. Dig Dis Sci. 2018 Dec 12;: Authors: Suárez Ferrer C, González-Lama Y, González-Partida I, Calvo Moya M, Vera Mendoza I, Matallana Royo V, Arevalo Serrano J, Abreu Garcia L Abstract BACKGROUND: Thiopurines are classically used in Crohn’s disease (CD). Treatment fails in a proportion of patients either due to adverse events (AE) or lack of efficacy. Increasing use of anti-TNFα biologic drugs may have had impact on thiopurines usage. AIM: To evaluate…